Latest Biotech News

Incyte moved into a late-stage blood disorder bet by agreeing to buy Star Therapeutics’ Vega subsidiary for $1.25 billion upfront, plus up to $750 million in sales milestones, to secure phase...

Roche committed $700 million upfront to partner with Nurix on bexobrutideg, an oral BTK degrader for B-cell malignancies, with milestones that could increase the total to $2.3 billion. The...

Tango Therapeutics and Revolution Medicines reported additional early-stage evidence for a pancreatic cancer combination built around vopimetostat, a PRMT5 inhibitor, paired with Revolution’s...

Interim expansion data from Tango’s PRMT5 inhibitor vopimetostat in combination with Revolution’s RAS(ON) inhibitors showed durable responses in an early clinical study in metastatic PDAC, with...

Texas A&M Health Institute researchers unveiled CODS, an AI-designed, caffeine-activated protein dissociation system intended to give engineered cells a controllable “pause” mechanism. Published...

City Therapeutics, an RNAi startup founded by former Alnylam executives, raised $99.5 million to accelerate clinical development of its first three RNAi candidates and expand beyond liver-focused...

Genomtec secured €2.6 million equity financing to support commercialization of its molecular diagnostics platforms, including a portable microfluidic system (Genomtec ID) and OncoSNAAT liquid...

Treeline Biosciences announced it will go public via a reverse merger with Standard BioTools, in an all-stock transaction valued around Standard BioTools’ net cash position plus additional value...

Nature Biotechnology published new work on sub-zero technologies designed to reduce ice damage in organs, with the goal of extending donor-graft shelf life and giving transplant centers more time...

Incyte has agreed to acquire Vega Therapeutics in a deal valued at $1.25 billion upfront, positioning Vega’s Phase III von Willebrand disease asset VGA039 as a potential next growth driver as...

Johnson & Johnson will pay $1 billion in cash to acquire Firefly Bio, adding “degrader-antibody conjugates” (DACs) to expand its oncology pipeline and deepen its exposure to targeted protein...

Roche has agreed to pay Nurix Therapeutics $700 million upfront and commit to up to $2.3 billion in milestones to co-develop and co-commercialize bexobrutideg, an oral BTK degrader for B-cell...

Tango Therapeutics is planning a Phase 3 pancreatic cancer study after early clinical results with vopimetostat (Tango) plus Revolution Medicines’ daraxonrasib. The report follows earlier...

A new toxicology report tied to AbbVie’s development of a bifunctional protein degrader molecule describes unusual liver findings during dog studies, flagging bile-duct degeneration and necrosis...

Texas A&M Health researchers have unveiled CODS, a caffeine-operated dissociation system designed to act as a molecular “pause button” for engineered cells. Published in the Journal of the...

Sonrotoclax (Beqalzi), a Bcl-2 inhibitor, won FDA approval in May 2026 for mantle cell lymphoma patients who have tried at least two prior therapies. The approval adds only the second Bcl-2...

Google DeepMind and the Wellcome Sanger Institute launched a five-year AI genomics consortium aimed at building large genomic datasets for training predictive biology machine learning models....

In a post-deal discussion, Incyte CEO Bill Meury said the company’s $2 billion Vega acquisition is designed to help build a “post-Jakafi future,” following his C-suite experience across multiple...

Institut Pasteur launched ACT-CHIK, a four-year project funded with €15.3 million by the Global Health EDCTP3 Joint Undertaking under the EU Horizon Europe program. The initiative is designed to...

Incyte agreed to buy Vega Therapeutics’ Star subsidiary in a deal worth $1.25 billion upfront, with up to $750 million in sales milestones, to add the phase III von Willebrand disease asset...